Application and mechanism of dipeptidyl peptidase-4 inhibitor in East Asia type 2 diabetic patients
10.3760/cma.j.issn.1000-6699.2017.12.013
- VernacularTitle:二肽基肽酶4抑制剂在东亚2型糖尿病患者中的应用与机制探讨
- Author:
Xiaopei CAO
1
Author Information
1. 中山大学附属第一医院内分泌科
- Keywords:
Dipeptidyl peptidase-4 inhibitors;
Diabetes mellitus;
type 2;
East Asia;
Mechanism
- From:
Chinese Journal of Endocrinology and Metabolism
2017;33(12):1071-1074
- CountryChina
- Language:Chinese
-
Abstract:
Dipeptidyl peptidase 4 (DPP-4) inhibitors are novel oral hypoglycemic agents, which have been used to inhibit degradation of endogenously released glucagon-like peptide-1 ( GLP-1 ) via inhibiting DPP-4 activity, consequently increasing level of GLP-1 in circulation, enhancing the effect of incretin hormone, and finally leading to improve glucose control. Meta-analysis showed that DPP-4 inhibitors exhibit better glucose-lowering effect in Asians compared with that in Caucasian. The racial differences of hypoglycemic effect could be mainly ascribed to the differences in the frequency of pancreatic-related gene mutations, the severity ofβ-cell dysfunction, the level of GLP-1, and the intake of carbohydrates in patients with diabetes mellitus.
